We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide Group achieves significant milestone in Malmö expansion project
22 Sep 2025 - Baar, 22 September 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful delivery and installation […]
Read moreAlzinova testimonial: Alzheimer’s peptide vaccine with PolyPeptide
1 Sep 2025 - September is International Alzheimer’s Month, a reminder of the urgent need to advance research and treatment options for patients and families affected worldwide. It is an […]
Read moreBackbone Protecting Groups for Enhanced Peptide and Protein Synthesis
13 Aug 2025 - This review provides a comprehensive account of the use of backbone N-protecting groups in peptide synthesis. It includes detailed synthetic methods relating to their introduction and removal […]
Read morePolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian site, 2025 full-year guidance revised towards the upper end of the range
12 Aug 2025 - Baar, 12 August 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its results for H1 2025, […]
Read morePolyPeptide announces expansion of existing credit facilities
23 May 2025 - Baar, 23 May 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients, today announced that it has secured additional […]
Read moreAlzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial
24 Apr 2025 - Sweden, 24 April 2025 – Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical […]
Read morePolyPeptide announces results of the annual General Meeting 2025
9 Apr 2025 - Baar, 9 April 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all […]
Read moreExpanding the Reach of Sustainable Solid-Phase Peptide Synthesis
2 Apr 2025 - Alloc protecting group expanded the peptide synthesis toolbox. Its removal can sometimes be seen as an issue: toxic solvents, air-sensitive Pd0) reagents, challenging upscaling. Not anymore […]
Read moreImpurities in Peptide Drug Substance and Challenges Faced during Registration (in US, EU, Brazil and China Markets) and Commercial Phase
20 Mar 2025 - Controlling impurities in complex drug substances is a crucial part of development and due to lack of harmonized approaches from Health authorities, the manufacturer faces many […]
Read more